Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
NCT ID: NCT00159666
Last Updated: 2021-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
255 participants
INTERVENTIONAL
2004-10-31
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT00629681
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
NCT01270828
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
NCT01455428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have completed the Daily Pain Rating Scale in the electronic diary at least 4 times during screening and have an average daily pain rating score of greater than or equl to 4 during the 7 +/- 3 days prior to randomization (Visit 2).
Exclusion Criteria
* Presence of any severe pain associated with conditions other than PHN that may confound the assessment or self-evaluation of the pain due to PHN.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Duarte, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Palm Beach Gardens, Florida, United States
Pfizer Investigational Site
Oak Brook, Illinois, United States
Pfizer Investigational Site
Flowood, Mississippi, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bochum, , Germany
Pfizer Investigational Site
Düsseldorf, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Göppingen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hattingen, , Germany
Pfizer Investigational Site
Jena, , Germany
Pfizer Investigational Site
Nuremberg, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
L’Aquila, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Pisa, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Leganés, Madrid, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Granada, , Spain
Pfizer Investigational Site
Salamanca, , Spain
Pfizer Investigational Site
Seville, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Middlesbrough, Cleveland, United Kingdom
Pfizer Investigational Site
Addlestone, Surrey, United Kingdom
Pfizer Investigational Site
Chicester, Sussex, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Oldham, Lancashire, , United Kingdom
Pfizer Investigational Site
Portsmouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schug SA, Parsons B, Almas M, Whalen E. Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord Injury-Related Neuropathic Pain. Pain Physician. 2017 Jan-Feb;20(1):E53-E63.
Markman JD, Jensen TS, Semel D, Li C, Parsons B, Behar R, Sadosky AB. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017 Jul;17(6):718-728. doi: 10.1111/papr.12516. Epub 2016 Dec 1.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.